What is the precise description of the genetic architecture of immunoglobulin A (IgA) nephropathy?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 13, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Genetic Architecture of IgA Nephropathy

IgA nephropathy has a complex polygenic genetic architecture characterized by multiple common genetic variants with small to moderate effects, rather than single-gene causation, with over 30 susceptibility loci identified through genome-wide association studies that predominantly involve genes regulating mucosal immunity and IgA production. 1

Key Genetic Characteristics

Polygenic Disease Model

IgAN exemplifies a complex or polygenic disease that lacks simple Mendelian inheritance patterns (dominant, recessive, or sex-linked). Instead, disease susceptibility results from the aggregate effect of many common genetic variants across multiple genomic regions combined with environmental factors 1. This distinguishes IgAN from monogenic kidney diseases where rare pathogenic variants in a single gene drive disease.

Identified Genetic Loci

Genome-wide association studies have identified more than 30 IgAN risk loci 2, 3. These discoveries emerged from large population-based GWAS, primarily conducted in European and East Asian ancestry populations 1. The genetic variants discovered are predominantly common single nucleotide polymorphisms (SNPs) rather than rare pathogenic mutations 2, 3.

Functional Pathways Implicated

Mucosal Immunity Predominance

Most susceptibility loci contain genes involved in:

  • Maintenance of intestinal epithelial barrier function
  • Response to mucosal pathogens
  • Intestinal immune network for IgA production 4, 5

This pattern strongly implicates the mucosal immune system in IgAN pathogenesis and has reformulated understanding of disease mechanisms 2, 4.

Heritability Estimates

The SNP-based heritability for IgAN falls within the range documented for complex kidney diseases. While specific heritability percentages for IgAN aren't explicitly stated in the guidelines, the disease demonstrates substantial familial aggregation and inherited susceptibility 5, 6.

Clinical Implications

Polygenic Risk Scores

The multiple identified loci enable development of polygenic risk scores that may help:

  • Identify individuals at significantly increased risk
  • Stratify patients for medical treatments
  • Guide therapeutic decision-making 2

Geographic and Ethnic Variation

The genetic architecture shows interpopulation allelic differentiation that parallels disease prevalence across populations. This multilocus adaptation pattern correlates with variation in local pathogens and explains why IgAN is most common in Asian populations, followed by Caucasians, and relatively infrequent in African populations 4, 6.

Important Caveats

IgAN does not fit neatly into either monogenic or polygenic categories - it exists on a spectrum where genetic risk variants range from rare variants with large effects to common variants with small effects 1. The proportion of variance explained by currently known loci remains smaller than the overall heritability, indicating substantial "missing heritability" that requires further investigation 3.

The genetic findings have directly informed the multihit pathogenesis model and identified the intestinal immune network as a therapeutic target 4. However, integrating genetics with epigenetics and environmental factors remains necessary to fully understand phenotypic variability and disease progression 3, 5.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.